Vaccine stocks

Ticker
Name
Market cap, $
Price, $
Price change, %20 Nov 2024
Type
Country
PE ratio
PB ratio
PS ratio
Revenue (quarterly), $
EPS diluted (quarterly), $
Johnson & Johnson368.62 B153.10-0.09StockUnited States25.315.254.2022.47 B1.11
Merck & Co246.13 B97.30+0.82StockUnited States20.405.533.9016.66 B1.24
AstraZeneca196.86 B63.49-0.72StockUnited Kingdom30.454.833.8413.56 B0.46
Pfizer140.77 B24.84-1.35StockUnited States33.571.532.3717.70 B0.78
GSK68.08 B33.37-0.68StockUnited Kingdom21.693.631.7110.43 B-0.04
BioNTech SE25.77 B107.50+0.31StockGermany1.217.801.37 B0.89
Moderna14.20 B36.90-0.97StockUnited States1.192.811.85 B0.03
Dynavax Technologies1.57 B11.97+1.27StockUnited States92.082.316.0380.63 M0.12
Novavax1.28 B8.01+0.88StockUnited States-2.441.5184.51 M-0.76
Phreesia1.07 B18.52+1.76StockUnited States4.262.74102.11 M-0.31
Ocugen270.61 M0.93+5.08StockUnited States6.6629.011.14 M-0.05
Vaxart138.79 M0.61-4.66StockUnited States2.036.894.93 M-0.06
On page:
On page:
Total: 12

Charts

Earnings and dividend calendar

Vaccine stocks news

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Pfizer names oncology chief and company veteran Boshoff as chief scientific officer
marketwatch.com20 November 2024 Sentiment: POSITIVE

The pharmaceutical company has been looking for a new chief scientific officer since July, following Mikael Dolsten's departure after 15 years with the firm.

Levi & Korsinsky Reminds Shareholders of an Investigation into AstraZeneca PLC (AZN) Regarding Potential Securities Fraud Allegations
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
globenewswire.com20 November 2024 Sentiment: POSITIVE

MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 (RP19), and cone-rod dystrophy 3 (CORD3).

Pfizer names Chris Boshoff as new R&D chief, WSJ reports
reuters.com20 November 2024 Sentiment: POSITIVE

According to a report from the WSJ on Wednesday, Pfizer has appointed Chris Boshoff, a long-time employee who has been in charge of the company's cancer research and marketing for over a year, as its new head of research and development.

Is It Time to Sell Eli Lilly and Pfizer Stocks?
fool.com20 November 2024 Sentiment: NEUTRAL

Should you consider selling your Eli Lilly and Pfizer stocks now?

European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
businesswire.com20 November 2024 Sentiment: POSITIVE

Pfizer Inc. has announced that the European Commission has approved HYMPAVZI™ (marstacimab) for use in preventing bleeding episodes in patients aged 12 and older who weigh at least 35 kg and have severe hemophilia A. This condition is caused by a deficiency in factor VIII (FVIII).

AstraZeneca hits out at NICE block to breast cancer drug
proactiveinvestors.co.uk20 November 2024 Sentiment: NEGATIVE

AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention of Wes Streeting, the health secretary.

GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
zacks.com20 November 2024 Sentiment: POSITIVE

The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.